Roivant Sciences Ltd Insider Trading
Every director, officer and 10% holder of Roivant Sciences Ltd has to report each trade in its stock within two business days of making it. This is those filings.
ROIV on carbonthat →Purchases and sales
Open-market trades only — the lines where someone chose to buy or sell at the going price.
| Insider | Action | Value |
|---|---|---|
| Melissa B, EpperlyDirector2026-10-0116.9K shat $36.08 | Sale10b5-1 plan | $607.9K |
| Melissa B, EpperlyDirector2026-10-01900 shat $36.57 | Sale10b5-1 plan | $32.9K |
| Melissa B, EpperlyDirector2026-09-154.3K shat $39.65 | Sale10b5-1 plan | $172K |
| Melissa B, EpperlyDirector2026-09-15600 shat $40.38 | Sale10b5-1 plan | $24.2K |
| Meghan FitzgeraldDirector2026-09-154.7K shat $39.68 | Sale10b5-1 plan | $187K |
| Meghan FitzgeraldDirector2026-09-15400 shat $40.45 | Sale10b5-1 plan | $16.2K |
| Meghan FitzgeraldDirector2026-09-0820K shat $39.90 | Sale10b5-1 plan | $798K |
| Eric VenkerPresident & Immunovant CEO2026-08-28166.2K shat $35.63 | Sale10b5-1 plan | $5.9M |
| Eric VenkerPresident & Immunovant CEO2026-08-2833.8K shat $36.44 | Sale10b5-1 plan | $1.2M |
| Mayukh SukhatmePresident & CIO2026-08-21144.8K shat $36.48 | Sale | $5.3M |
| Mayukh SukhatmePresident & CIO2026-08-2017.5K shat $37.30 | Sale | $653.5K |
| Mayukh SukhatmePresident & CIO2026-08-19172.9K shat $37.17 | Sale | $6.4M |
| Mayukh SukhatmePresident & CIO2026-08-18105.1K shat $36.59 | Sale | $3.8M |
| Mayukh SukhatmePresident & CIO2026-08-1831.8K shat $37.18 | Sale | $1.2M |
| Mayukh SukhatmePresident & CIO2026-08-17284.7K shat $36.25 | Sale | $10.3M |
| Mayukh SukhatmePresident & CIO2026-08-14243.2K shat $36.23 | Sale | $8.8M |
| Eric VenkerPresident & Immunovant CEO2026-07-27200K shat $34.95 | Sale10b5-1 plan | $7M |
| Meghan FitzgeraldDirector2026-06-3010K shat $34.90 | Sale10b5-1 plan | $349K |
| Keith S ManchesterDirector2026-06-3012.4K shat $35.28 | Sale | $436.8K |
| Keith S ManchesterDirector2026-06-30200K shat $35.45 | Sale | $7.1M |
| Daniel Allen GoldDirector2026-06-3012.4K shat $35.28 | Sale | $436.8K |
| QVT Financial LP2026-06-3012.4K shat $35.28 | Sale | $436.8K |
| Melissa B, EpperlyDirector2026-06-2915K shat $34.32 | Sale10b5-1 plan | $514.9K |
| Melissa B, EpperlyDirector2026-06-292.7K shat $34.71 | Sale10b5-1 plan | $95.4K |
| Keith S ManchesterDirector2026-06-29200K shat $34.44 | Sale | $6.9M |
| Keith S ManchesterDirector2026-06-29600K shat $34.59 | Sale | $20.8M |
| Daniel Allen GoldDirector2026-06-29200K shat $34.44 | Sale | $6.9M |
| Daniel Allen GoldDirector2026-06-29600K shat $34.59 | Sale | $20.8M |
| QVT Financial LP2026-06-29200K shat $34.44 | Sale | $6.9M |
| QVT Financial LP2026-06-29600K shat $34.59 | Sale | $20.8M |
| Mayukh SukhatmePresident & CIO2026-06-26500K shat $34.08 | Sale | $17M |
| Keith S ManchesterDirector2026-06-26300.8K shat $33.92 | Sale | $10.2M |
| Keith S ManchesterDirector2026-06-26325K shat $34.07 | Sale | $11.1M |
| Daniel Allen GoldDirector2026-06-26300.8K shat $33.92 | Sale | $10.2M |
| Daniel Allen GoldDirector2026-06-26325K shat $34.07 | Sale | $11.1M |
| QVT Financial LP2026-06-26300.8K shat $33.92 | Sale | $10.2M |
| QVT Financial LP2026-06-26325K shat $34.07 | Sale | $11.1M |
| Mayukh SukhatmePresident & CIO2026-06-25500K shat $34.13 | Sale | $17.1M |
Source: SEC Form 4 filings, via EDGAR. A derivative line reports the shares underlying an option rather than stock outstanding, so it is marked and is not comparable with the rest. Value is shares times the reported price, and is blank where the filing priced the transaction at zero — a grant costs its recipient nothing. Insiders sell for reasons that have nothing to do with the company, which is why a sale is not read as a signal on its own.
More on ROIV
Follow Roivant Sciences Ltd (ROIV) by email
New trades in Roivant Sciences Ltd (ROIV) by members of Congress, insiders and funds, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.